Opthea (OPT) Competitors $3.41 +0.23 (+7.23%) As of 08/27/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OPT vs. IRON, MESO, ARQT, ADPT, CGON, ANIP, VCEL, BEAM, DYN, and APGEShould you be buying Opthea stock or one of its competitors? The main competitors of Opthea include Disc Medicine (IRON), Mesoblast (MESO), Arcutis Biotherapeutics (ARQT), Adaptive Biotechnologies (ADPT), CG Oncology (CGON), ANI Pharmaceuticals (ANIP), Vericel (VCEL), Beam Therapeutics (BEAM), Dyne Therapeutics (DYN), and Apogee Therapeutics (APGE). These companies are all part of the "pharmaceutical products" industry. Opthea vs. Its Competitors Disc Medicine Mesoblast Arcutis Biotherapeutics Adaptive Biotechnologies CG Oncology ANI Pharmaceuticals Vericel Beam Therapeutics Dyne Therapeutics Apogee Therapeutics Opthea (NASDAQ:OPT) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability. Do institutionals and insiders have more ownership in OPT or IRON? 56.0% of Opthea shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 3.2% of Opthea shares are owned by insiders. Comparatively, 3.6% of Disc Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger earnings & valuation, OPT or IRON? Disc Medicine has lower revenue, but higher earnings than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpthea$120K4,373.61-$220.24MN/AN/ADisc MedicineN/AN/A-$109.36M-$4.47-13.35 Which has more risk & volatility, OPT or IRON? Opthea has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Is OPT or IRON more profitable? Opthea's return on equity of 0.00% beat Disc Medicine's return on equity.Company Net Margins Return on Equity Return on Assets OptheaN/A N/A N/A Disc Medicine N/A -26.60%-24.58% Does the media refer more to OPT or IRON? In the previous week, Disc Medicine had 8 more articles in the media than Opthea. MarketBeat recorded 9 mentions for Disc Medicine and 1 mentions for Opthea. Opthea's average media sentiment score of 1.87 beat Disc Medicine's score of 1.29 indicating that Opthea is being referred to more favorably in the media. Company Overall Sentiment Opthea Very Positive Disc Medicine Positive Do analysts prefer OPT or IRON? Opthea currently has a consensus target price of $1.33, suggesting a potential downside of 60.90%. Disc Medicine has a consensus target price of $98.30, suggesting a potential upside of 64.77%. Given Disc Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Disc Medicine is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 SummaryDisc Medicine beats Opthea on 7 of the 12 factors compared between the two stocks. Get Opthea News Delivered to You Automatically Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPT vs. The Competition Export to ExcelMetricOptheaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$524.85M$3.10B$5.78B$9.79BDividend YieldN/A2.26%3.95%4.02%P/E RatioN/A21.0831.2626.59Price / Sales4,373.61361.89431.16158.34Price / CashN/A44.6737.7359.36Price / Book-6.098.0910.046.68Net Income-$220.24M-$54.08M$3.27B$265.59M7 Day PerformanceN/A-0.41%1.34%0.66%1 Month PerformanceN/A6.23%6.13%2.64%1 Year Performance12.54%10.45%41.90%22.36% Opthea Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPTOpthea0.3947 of 5 stars$3.41+7.2%$1.33-60.9%+15.2%$524.85M$120K0.008Gap UpHigh Trading VolumeIRONDisc Medicine3.6706 of 5 stars$58.84-1.7%$96.18+63.5%+20.6%$2.08BN/A-13.1630News CoveragePositive NewsInsider TradeMESOMesoblast2.1429 of 5 stars$15.93-2.0%$18.00+13.0%+150.4%$2.08B$5.67M0.0080ARQTArcutis Biotherapeutics2.4974 of 5 stars$16.74-0.9%$19.80+18.3%+44.9%$2.03B$196.54M-22.32150Positive NewsADPTAdaptive Biotechnologies2.5408 of 5 stars$12.41-4.8%$12.38-0.3%+195.1%$1.99B$178.96M-15.13790CGONCG Oncology1.2461 of 5 stars$26.13+1.7%$55.30+111.6%-27.4%$1.96B$1.14M-14.7661Positive NewsANIPANI Pharmaceuticals3.2463 of 5 stars$89.71+2.6%$84.75-5.5%+47.5%$1.90B$614.38M-116.50600Insider TradeVCELVericel2.3628 of 5 stars$36.32+0.1%$60.33+66.1%-31.7%$1.83B$237.22M302.69300Positive NewsBEAMBeam Therapeutics2.247 of 5 stars$17.10-4.0%$48.45+183.4%-35.3%$1.80B$63.52M-3.80510Positive NewsDYNDyne Therapeutics3.5786 of 5 stars$12.33-0.4%$33.80+174.1%-69.5%$1.76BN/A-3.19100Positive NewsAPGEApogee Therapeutics3.7513 of 5 stars$36.90-1.0%$99.00+168.3%-24.4%$1.72BN/A-8.9391Positive NewsAnalyst Forecast Related Companies and Tools Related Companies IRON Alternatives MESO Alternatives ARQT Alternatives ADPT Alternatives CGON Alternatives ANIP Alternatives VCEL Alternatives BEAM Alternatives DYN Alternatives APGE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPT) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access